Build my stack
Home · Guides · Metformin vs Semaglutide

Metformin vs Semaglutide: Not the Same Drug

Ready to buy? the vendor scorecard ranks every seller we review on lab tests, shipping and price, with reader codes.
Disclosure: affiliate links below may earn the Bureau a commission at no cost to you.

The short answer

No. Metformin is not semaglutide, and a DailyMed search on 1 November 2026 found no product that combines the two. Metformin is a biguanide tablet labelled for type 2 diabetes; semaglutide is a GLP-1 receptor agonist given weekly by injection or daily as a tablet. In trials, metformin averaged about 2% weight loss (2.1 kg over 2.8 years in the Diabetes Prevention Program), while semaglutide 2.4 mg averaged 14.9% over 68 weeks in STEP 1. The two have been studied together, and semaglutide's labels describe trial patients who stayed on metformin.

People search this pair a dozen ways: metformin vs semaglutide, semaglutide vs metformin, "is metformin a semaglutide", "is semaglutide in metformin". The short version is that they are unrelated drugs that happen to share a patient population and a reputation for weight changes. The sections below put the label facts and the trial numbers side by side. This is research use information, it reports what labels and trials say, and none of it is medical advice. For the mechanism in detail see how semaglutide works.

Is metformin a semaglutide? Is semaglutide in metformin?

Neither. The metformin tablet label calls metformin "a biguanide" and says it decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity. The Ozempic and Wegovy labels call semaglutide a GLP-1 analogue that "acts as a GLP-1 receptor agonist". Different molecule, different receptor, different class.

There is also no hidden semaglutide in a metformin product. Searching DailyMed on 1 November 2026, none of the 559 labels returned for "metformin" has semaglutide in its title, and none of the 9 labels returned for "semaglutide" has metformin in its title. Metformin does turn up in fixed combination pills, for example with sitagliptin or pioglitazone, which is probably where the mix-up starts. Semaglutide is not one of the partners.

Metformin vs semaglutide at a glance

Metformin tabletsSemaglutide injection (Ozempic, Wegovy)Oral semaglutide (Rybelsus, Wegovy tablets)
Drug classBiguanideGLP-1 receptor agonistGLP-1 receptor agonist
How it works (label)Decreases hepatic glucose production and intestinal glucose absorption, improves insulin sensitivityActivates the GLP-1 receptor; Wegovy label notes GLP-1 receptors in brain areas that regulate appetiteSame active ingredient and mechanism as the injection
Dose formTablet with meals. Label start 500 mg twice daily or 850 mg once daily, maximum 2550 mg a dayWeekly subcutaneous injection. Wegovy starts at 0.25 mg and usually maintains at 2.4 mgDaily tablet, empty stomach, up to 4 oz water, 30 minute wait. Wegovy tablets maintain at 25 mg
Weight loss in its main trial2.1 kg at 2.8 years vs 0.1 kg placebo (Diabetes Prevention Program); 2.06% vs 0.02% in the follow-up study14.9% vs 2.4% placebo at 68 weeks (STEP 1, Wegovy 2.4 mg); 9.6% vs 3.4% in type 2 diabetesWegovy 25 mg tablets: 13.6% vs 2.4% placebo at 64 weeks. Rybelsus is labelled for diabetes, not weight
Approved uses (US labels)Glycaemic control in type 2 diabetes, adults and children 10 and older. Not labelled for weight lossOzempic: type 2 diabetes control, cardiovascular and kidney risk reduction. Wegovy: weight reduction and maintenance, cardiovascular risk reduction, MASHRybelsus: type 2 diabetes control and cardiovascular risk reduction. Wegovy tablets: weight reduction, cardiovascular risk reduction
Boxed warningLactic acidosisRisk of thyroid C-cell tumoursRisk of thyroid C-cell tumours
Common side effects (label)Diarrhoea 53% vs 12% placebo, nausea or vomiting 26% vs 8%, flatulence 12% vs 6%; subnormal B12 in about 7%Wegovy 2.4 mg: nausea 44% vs 16%, diarrhoea 30% vs 16%, vomiting 24% vs 6%, constipation 24% vs 11%Rybelsus (5% or more): nausea, abdominal pain, diarrhoea, decreased appetite, vomiting, constipation
SourceMetformin hydrochloride tablets label (DailyMed); NEJM 2002; Diabetes Care 2012Wegovy and Ozempic labels (DailyMed); NEJM 2021Rybelsus and Ozempic tablets label; Wegovy label (DailyMed)

These are separate trials in different people, so treat the weight rows as context rather than a head-to-head. The Diabetes Prevention Program enrolled adults with raised glucose and a mean BMI of 34; STEP 1 enrolled adults with overweight or obesity, and no trial in this table put the two drugs against each other.

Metformin vs semaglutide for weight loss

Metformin is not approved for weight loss. Its weight effect is a side effect of its metabolic actions. The best long-term evidence is the Diabetes Prevention Program (3,234 adults, mean follow-up 2.8 years), where average weight loss was 0.1 kg on placebo, 2.1 kg on metformin 850 mg twice daily and 5.6 kg on the lifestyle program. In the follow-up study, metformin participants lost 2.06 percent of body weight against 0.02 percent on placebo, and the authors reported the loss was directly related to adherence.

The average hides a minority who did much better. In the Diabetes Prevention Program Outcomes Study, 28.5 percent of the metformin group lost at least 5 percent of body weight in the first year, and that subgroup kept a mean 6.2 percent off between years 6 and 15. The lifestyle and placebo subgroups kept 3.7 and 2.8 percent.

Semaglutide was built for weight and it shows. In STEP 1, 1,961 adults with overweight or obesity on semaglutide 2.4 mg lost a mean 14.9 percent over 68 weeks against 2.4 percent on placebo. The Wegovy label reports the same 14.9 and 2.4 percent figures. In adults with type 2 diabetes the label shows a smaller loss, 9.6 percent against 3.4 percent.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Rybelsus vs metformin

Both are daily tablets, which is where the similarity ends. Rybelsus is oral semaglutide. The current label covers Rybelsus and Ozempic tablets. For Rybelsus, the start is 3 mg once daily for 30 days (a dose the label says is not effective for glycaemic control), then 7 mg, with 14 mg after that if needed, on an empty stomach with up to 4 ounces of plain water and a 30 minute wait before eating. The indication is glycaemic control in type 2 diabetes and cardiovascular risk reduction in type 2 diabetes. Metformin is taken with meals and the label's boxed warning is lactic acidosis, not thyroid C-cell tumours.

If the question is an oral semaglutide for weight, that is a different label. Wegovy tablets, titrated from 1.5 mg to a 25 mg maintenance dose, are labelled for weight reduction in adults, and the label reports 13.6 percent loss against 2.4 percent on placebo at 64 weeks. More on the tablet forms in oral semaglutide.

Best vendor for semaglutide right now: Amino Club

10mg vial, $49.99 per vial ($5.00 per mg), list price checked 2026-09-08. Lowest price per mg of the vendors we track for this compound, and the vendor Bureau readers order from most, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.

Check price at Amino Club Compare all vendors

Can you take metformin and semaglutide together?

The labels treat it as an ordinary pairing in type 2 diabetes. The Ozempic label says the drug has been studied alone and in combination with metformin, with metformin and sulfonylureas, and with metformin and a thiazolidinedione, and reports a 40 week trial of 959 patients on Ozempic as an add-on to metformin with or without a sulfonylurea in which no new safety signals were identified. The Wegovy type 2 diabetes trial enrolled patients on diet and exercise or one to three oral drugs including metformin. The Wegovy and Rybelsus labels also list metformin among the drugs with no clinically significant pharmacokinetic differences when used with semaglutide.

Both labels warn about hypoglycaemia when either drug is added to insulin or an insulin secretagogue such as a sulfonylurea, which is a separate issue from combining the two with each other. Both also list diarrhoea and nausea among their common reactions. The Wegovy label does not report a trial built to measure whether metformin adds weight loss on top of semaglutide, so that question is open. Decisions on combining them sit with a prescriber.

Cost and access

Metformin is sold as generic tablets, and the cost gap to brand semaglutide is large, so for many people cost decides this before efficacy does. We do not quote prices here. The routes and trade-offs for semaglutide are in semaglutide cost without insurance. If you are working out a semaglutide dose or syringe units for research, the semaglutide dosage calculator does the arithmetic, the semaglutide dosage guide lays out the label titration steps, and best place to buy semaglutide compares the research-market sources we score.

Side effects and warnings

Both are gastrointestinal drugs in what people notice. Metformin diarrhoea and nausea come early and decline over time in the follow-up study, and the label lists a drop to subnormal B12 in about 7 percent in 29-week trials. Semaglutide nausea, vomiting and constipation cluster around dose escalation; in the Wegovy label 6.8 percent of the 2.4 mg group stopped treatment for adverse reactions against 3.2 percent on placebo. Neither is free of a boxed warning: metformin carries lactic acidosis, mainly tied to risk factors such as renal impairment, and semaglutide carries thyroid C-cell tumours seen in rodents, with a contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2. Detail is in semaglutide side effects.

Which question are you asking?

  • Smallest effect, long-established tablet? Metformin: about 2 percent on average in the trials above, and a minority who respond more.
  • Largest weight effect in a label? Semaglutide 2.4 mg, or tirzepatide, which beat it head to head at 20.2 percent against 13.7 percent in SURMOUNT-5. See semaglutide vs tirzepatide.
  • Prediabetes prevention? Metformin has that evidence: the Diabetes Prevention Program found a 31 percent lower diabetes incidence than placebo, against 58 percent for the lifestyle program.
  • Worried about stopping? See the regain figures in the FAQ below.

See also: Rybelsus vs Ozempic.

Frequently Asked Questions

Is metformin the same as semaglutide?

No. Metformin is a biguanide tablet that the US label describes as a treatment for type 2 diabetes, working mainly by lowering liver glucose output and improving insulin sensitivity. Semaglutide is a GLP-1 receptor agonist, sold as Ozempic, Wegovy and Rybelsus. They are different molecules from different drug classes, and being on one is not being on the other.

Is semaglutide in metformin, or is there a combination pill?

No. Metformin tablets contain metformin only. On 1 November 2026 a search of DailyMed titles for metformin (559 labels) returned no semaglutide product, and the search for semaglutide (9 labels) returned no metformin product. Metformin does appear in combination pills with other drugs, such as sitagliptin or pioglitazone, but not with semaglutide.

Is semaglutide better than metformin for weight loss?

In trials, by a wide margin, though the trials were different. Semaglutide 2.4 mg produced a 14.9 percent mean loss over 68 weeks in STEP 1 against 2.4 percent on placebo. Metformin 850 mg twice daily produced a mean 2.1 kg loss over 2.8 years in the Diabetes Prevention Program, against 0.1 kg on placebo. Metformin is not labelled for weight loss; Wegovy is.

How much weight can you lose on metformin?

On average about 2 percent. In the Diabetes Prevention Program the mean loss was 2.1 kg at 2.8 years, and in the follow-up study the metformin group lost 2.06 percent of body weight against 0.02 percent on placebo. The average hides a split: 28.5 percent of the metformin group lost at least 5 percent of body weight in year 1, and that subgroup kept a mean 6.2 percent off between years 6 and 15.

What is the difference between Rybelsus and metformin?

Both are tablets, but Rybelsus is semaglutide, a GLP-1 receptor agonist taken once daily on an empty stomach with up to 4 ounces of plain water, with a 30 minute wait before food. Metformin is a biguanide taken with meals. The Rybelsus label is for type 2 diabetes and carries a boxed warning for thyroid C-cell tumours; the metformin label carries a boxed warning for lactic acidosis.

Can you take metformin and semaglutide together?

The labels show they have been studied together. The Ozempic label says it was studied alone and in combination with metformin, including a 40 week trial of 959 patients on metformin with or without a sulfonylurea that found no new safety signals. The Wegovy label also reports no clinically significant pharmacokinetic differences when used with metformin. Whether to combine them is a prescriber decision, and nothing here is medical advice.

Which has worse side effects, metformin or semaglutide?

They differ in kind. In the metformin label trial in type 2 diabetes, diarrhoea affected 53 percent against 12 percent on placebo, and about 7 percent had a drop to subnormal vitamin B12. In the Wegovy label, nausea affected 44 percent against 16 percent on placebo, diarrhoea 30 against 16, vomiting 24 against 6 and constipation 24 against 11. The boxed warnings also differ: lactic acidosis for metformin, thyroid C-cell tumours for semaglutide.

Does weight come back after stopping?

For semaglutide, yes, in the STEP 1 extension: a year after stopping, participants had regained 11.6 percentage points, about two thirds of the 17.3 percent they had lost. For metformin, the Diabetes Prevention Program Outcomes Study authors reported the modest loss was durable for at least 10 years, and that weight loss was directly related to adherence to metformin.

Sources (checked 1 November 2026)

  1. Metformin hydrochloride tablets, US prescribing information (boxed warning, indication, mechanism, dosing, adverse reactions, revised 04/2026). DailyMed. Checked 1 November 2026.
  2. Wegovy (semaglutide) injection and tablets, US prescribing information (indications, boxed warning, mechanism, dosing, Tables 3, 8 and 11, limitations of use). DailyMed. Checked 1 November 2026.
  3. Ozempic (semaglutide) injection, US prescribing information (indications, mechanism, studies with metformin, drug interactions). DailyMed. Checked 1 November 2026.
  4. Rybelsus and Ozempic tablets (oral semaglutide), US prescribing information (indications, dosing, boxed warning, drug interactions with metformin). DailyMed. Checked 1 November 2026.
  5. DailyMed label search for "metformin" (559 titles) and "semaglutide" (9 titles), checked for the other drug in the title. DailyMed. Searched 1 November 2026 (database dated 30 October 2026).
  6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med, 2021. PMID 33567185. Checked 1 November 2026.
  7. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab, 2022. PMID 35441470. Checked 1 November 2026.
  8. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002. PMID 11832527; weight figures read in the full text on PMC. Checked 1 November 2026.
  9. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 2012. PMID 22442396. Checked 1 November 2026.
  10. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med, 2019. doi 10.7326/M18-1605; abstract figures read in the GWU repository record. Checked 1 November 2026.
  11. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med, 2025;393(1):26-36. doi 10.1056/NEJMoa2416394; figures read in the ACC journal scan. Checked 1 November 2026.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes